Pharvaris (NASDAQ:PHVS - Get Free Report)'s share price gapped up prior to trading on Tuesday . The stock had previously closed at $14.50, but opened at $15.17. Pharvaris shares last traded at $14.73, with a volume of 1,950 shares changing hands.
Analyst Ratings Changes
Separately, JMP Securities raised their price target on Pharvaris from $46.00 to $55.00 and gave the stock a "market outperform" rating in a research note on Friday, January 31st.
Read Our Latest Analysis on Pharvaris
Pharvaris Trading Up 6.4 %
The stock's 50 day moving average is $14.94 and its two-hundred day moving average is $18.10. The stock has a market cap of $880.56 million, a price-to-earnings ratio of -6.01 and a beta of -2.84.
Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its quarterly earnings data on Monday, April 7th. The company reported ($0.68) EPS for the quarter, topping analysts' consensus estimates of ($0.74) by $0.06. On average, sell-side analysts predict that Pharvaris will post -2.71 EPS for the current year.
Institutional Trading of Pharvaris
Hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. lifted its holdings in Pharvaris by 1,125.3% in the fourth quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock valued at $59,000 after acquiring an additional 2,847 shares during the period. Cubist Systematic Strategies LLC acquired a new position in shares of Pharvaris during the 4th quarter worth $64,000. Barclays PLC purchased a new position in shares of Pharvaris in the 3rd quarter valued at about $106,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Pharvaris in the fourth quarter valued at about $111,000. Finally, Point72 Asset Management L.P. purchased a new stake in Pharvaris during the fourth quarter worth about $152,000.
About Pharvaris
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
Featured Articles
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
